Protalix BioTherapeutics, Inc.
PLX
$2.96
$0.1053.68%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 207.45% | 274.73% | -111.39% | -46.76% | -61.60% |
| Total Depreciation and Amortization | 6.71% | 7.87% | 8.87% | 15.00% | 13.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -22.37% |
| Total Other Non-Cash Items | -59.14% | 231.44% | 113.38% | -20.63% | 212.34% |
| Change in Net Operating Assets | -144.34% | 72.42% | 81.36% | 1,251.57% | 2,491.33% |
| Cash from Operations | 11.02% | 159.60% | -172.59% | 239.69% | 237.69% |
| Capital Expenditure | -70.00% | 80.54% | 15.69% | -141.13% | -17.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16,090.22% | 199.90% | 55.56% | -100.16% | -101.78% |
| Cash from Investing | -4,379.53% | 197.36% | 18.92% | -112.81% | -106.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | 300.00% | 77.78% | 44.44% | 83.33% | -3.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -337.10% | 114.44% | -125.15% | -77.55% | -49.52% |